Do SABR-related toxicities for lung cancer depend on treatment delivery?

Lung cancer is the most common cancer worldwide, both in new cases and deaths (Ferlay et al., 2012). Non-small cell lung carcinomas (NSCLC) account for approximately 60% of all lung cancers and tend to progress in a slower fashion compared to small cell lung carcinomas (SCLC) (approximately 12% of lung cancers) a more aggressive type of lung cancer, known to metastasise to the brain (Kumar et al., 2013). There are several treatment options to be considered for lung cancer patients and they are: surgery (e.g.

Source: Critical Reviews in Oncology Hematology - June 23, 2018 Category: Cancer & Oncology Authors: Stamati Morias, Loredana Gabriela Marcu, Michala Short, Eileen Giles, Eva Bezak Source Type: research